348 related articles for article (PubMed ID: 11734652)
1. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.
Mercader M; Bodner BK; Moser MT; Kwon PS; Park ES; Manecke RG; Ellis TM; Wojcik EM; Yang D; Flanigan RC; Waters WB; Kast WM; Kwon ED
Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14565-70. PubMed ID: 11734652
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
Gannon PO; Poisson AO; Delvoye N; Lapointe R; Mes-Masson AM; Saad F
J Immunol Methods; 2009 Aug; 348(1-2):9-17. PubMed ID: 19552894
[TBL] [Abstract][Full Text] [Related]
3. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin ME; Bubley GJ; Ko YJ; Small EJ; Upton M; Rajeshkumar B; Balk SP
Cancer Res; 1999 Jun; 59(11):2511-5. PubMed ID: 10363963
[TBL] [Abstract][Full Text] [Related]
4. Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model.
Hahn S; Nesslinger NJ; Drapala RJ; Bowden M; Rennie PS; Pai HH; Ludgate C; Nelson BH
Int J Cancer; 2009 Dec; 125(12):2871-8. PubMed ID: 19554630
[TBL] [Abstract][Full Text] [Related]
5. Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma.
Ebelt K; Babaryka G; Figel AM; Pohla H; Buchner A; Stief CG; Eisenmenger W; Kirchner T; Schendel DJ; Noessner E
Prostate; 2008 Jan; 68(1):1-10. PubMed ID: 17948280
[TBL] [Abstract][Full Text] [Related]
6. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.
Sfanos KS; Bruno TC; Meeker AK; De Marzo AM; Isaacs WB; Drake CG
Prostate; 2009 Nov; 69(15):1694-703. PubMed ID: 19670224
[TBL] [Abstract][Full Text] [Related]
7. T cells CD4+/CD8+ local immune modulation by prostate cancer hemi-cryoablation.
Cerqueira MA; Ferrari KL; de Mattos AC; Monti CR; Reis LO
World J Urol; 2020 Mar; 38(3):673-680. PubMed ID: 31263944
[TBL] [Abstract][Full Text] [Related]
8. Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue.
Valdman A; Jaraj SJ; Compérat E; Charlotte F; Roupret M; Pisa P; Egevad L
APMIS; 2010 May; 118(5):360-5. PubMed ID: 20477811
[TBL] [Abstract][Full Text] [Related]
9. Alterations in the T-cell receptor variable beta gene-restricted profile of CD8+ T lymphocytes in the peripheral circulation of patients with squamous cell carcinoma of the head and neck.
Albers AE; Visus C; Tsukishiro T; Ferris RL; Gooding W; Whiteside TL; De Leo AB
Clin Cancer Res; 2006 Apr; 12(8):2394-403. PubMed ID: 16638844
[TBL] [Abstract][Full Text] [Related]
10. Cytoprotective effects of high dose of α-galactosylceramide against activation-induced CD4+ T and CD8+ T cell death as an adjuvant.
Qian G; Jin W; Tian X; Ding Z; Shi B; Zhang Q
Int J Clin Exp Pathol; 2015; 8(5):5026-34. PubMed ID: 26191196
[TBL] [Abstract][Full Text] [Related]
11. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
12. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
[TBL] [Abstract][Full Text] [Related]
13. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells.
Unitt E; Rushbrook SM; Marshall A; Davies S; Gibbs P; Morris LS; Coleman N; Alexander GJ
Hepatology; 2005 Apr; 41(4):722-30. PubMed ID: 15791620
[TBL] [Abstract][Full Text] [Related]
14. Sipuleucel-T in metastatic castration-resistant prostate cancer: profile report.
Plosker GL
BioDrugs; 2011 Aug; 25(4):255-6. PubMed ID: 21815700
[No Abstract] [Full Text] [Related]
15. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
16. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
[TBL] [Abstract][Full Text] [Related]
17. [Basic and clinical characteristics of flutamide].
Suzuki K; Nakazato H; Kurokawa K; Yamanaka H
Nihon Rinsho; 2000 Jul; 58 Suppl():211-5. PubMed ID: 11022716
[No Abstract] [Full Text] [Related]
18. The antiandrogen withdrawal syndrome.
Wirth MP; Froschermaier SE
Urol Res; 1997; 25 Suppl 2():S67-71. PubMed ID: 9144890
[TBL] [Abstract][Full Text] [Related]
19. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
Middleman MN; Lush RM; Figg WD
Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
[TBL] [Abstract][Full Text] [Related]
20. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
